Study of TJ033721 (givastomig) in Subjects with Advanced or Metastatic Solid Tumors
Phase 1
168
about 5.5 years
18+
11 sites in CA, CO, IN +7
What this study is about
This trial is testing a treatment called TJ033721 (givastomig) in people with advanced or metastatic solid tumors. The goal is to see if it's safe and how well it works, along with its effects on the body.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take TJ033721 (givastomig)
- 2.Take TJ033721 (givastomig) , nivolumab, chemotherapy
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
durvalumab, nivolumab (Immune checkpoint inhibitor; blocks PD-1 receptor on T cells)
infusion
Primary: Dose-limiting toxicities (DLTs), Incidence and severity of AEs, Maximum tolerated or administered dose (MTD, MAD)
Secondary: Pharmacokinetic (PK) Parameters: AUCt, Pharmacokinetic (PK) Parameters: AUC∞, Pharmacokinetic (PK) Parameters: Cmax, Pharmacokinetic Parameters: T1/2, Pharmacokinetic Parameters: Tmax
Oncology